AR and prostate carcinoma: Han et al. have utilized ARI-16 as an AR ligand and developed AR-targeting PROTAC ARD-69 with a DC50 value of less than 1 nM in AR+ prostate cancer cell lines such as LNCaP and VCaP cells.